

Jan Rekowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4888690/publications.pdf>

Version: 2024-02-01

27
papers

845
citations

623734

14
h-index

610901

24
g-index

28
all docs

28
docs citations

28
times ranked

1244
citing authors

#	ARTICLE	IF	CITATIONS
1	Positron Emission Tomographyâ€“Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2024-2034.	1.6	176
2	Targeting the p300/CBP Axis in Lethal Prostate Cancer. <i>Cancer Discovery</i> , 2021, 11, 1118-1137.	9.4	124
3	Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. <i>Cancer Discovery</i> , 2021, 11, 2812-2827.	9.4	78
4	Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. <i>European Urology</i> , 2021, 79, 200-211.	1.9	76
5	Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. <i>European Journal of Cancer</i> , 2020, 124, 25-36.	2.8	67
6	Arthroscopic three-dimensional autologous chondrocyte transplantation using spheroids for the treatment of full-thickness cartilage defects of the hip joint. <i>Knee Surgery, Sports Traumatology, Arthroscopy</i> , 2016, 24, 2032-2037.	4.2	52
7	Characterizing CDK12-Mutated Prostate Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 566-574.	7.0	50
8	Is early treatment of cam-type femoroacetabular impingement the key to avoiding associated full thickness isolated chondral defects?. <i>Knee Surgery, Sports Traumatology, Arthroscopy</i> , 2016, 24, 2332-2337.	4.2	32
9	Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas â€“ a Randomized Controlled Trial Comparing Different Treatment Approaches Based on Interim PET Results (PETAL) <i>Tj ETQq1 1 0.784314 rgBT3jOverlo</i>		
10	Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ^{18}F SUV _{max} Method. <i>Journal of Nuclear Medicine</i> , 2021, 62, 37-42.	5.0	29
11	HER3 Is an Actionable Target in Advanced Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 6207-6218.	0.9	25
12	Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the â€œPositron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomasâ€•(PETAL) trial. <i>Annals of Hematology</i> , 2019, 98, 897-907.	1.8	24
13	Baseline and interim PETâ€“based outcome prediction in peripheral Tâ€“cell lymphoma: A subgroup analysis of the PETAL trial. <i>Hematological Oncology</i> , 2020, 38, 244-256.	1.7	18
14	CSF and blood Kallikrein-8: a promising early biomarker for Alzheimerâ€™s disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 40-48.	1.9	16
15	The predictive performance of SAPS 2 and SAPS 3 in an intermediate care unit for internal medicine at a German university transplant center; A retrospective analysis. <i>PLoS ONE</i> , 2019, 14, e0222164.	2.5	12
16	Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy. <i>Endocrine</i> , 2022, 75, 293-302.	2.3	8
17	Hepatic artery and biliary complications in liver transplant recipients with radioembolization bridging treatment for hepatocellular carcinoma. <i>Clinical Transplantation</i> , 2017, 31, e13096.	1.6	7
18	Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome. <i>Blood Cancer Journal</i> , 2019, 9, 67.	6.2	5

#	ARTICLE	IF	CITATIONS
19	Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapy. <i>Cancer Medicine</i> , 2020, 9, 8386-8396.	2.8	5
20	Metabolic tumor volume, cancer cell fraction, and prognosis – the case of T-cell/histiocyte-rich large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1372-1379.	1.3	3
21	Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NPHOS trial. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 982-991.	0.7	3
22	Score performance of SAPS 2 and SAPS 3 in combination with biomarkers IL-6, PCT or CRP. <i>PLoS ONE</i> , 2020, 15, e0238587.	2.5	2
23	Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2611-2621.	2.5	2
24	Supporting data for positron emission tomography-based risk modelling using a fixed-instead of a relative thresholding method for total metabolic tumor volume determination. <i>Data in Brief</i> , 2020, 28, 104976.	1.0	1
25	Phase II dose-response trials: A simulation study to compare analysis method performance under design considerations. <i>Journal of Biopharmaceutical Statistics</i> , 2017, 27, 885-901.	0.8	0
26	Immunoglobulin M Heavy/Light Chain Pair Measurement Independently Predicts Clinical Outcome and Refines Prognostic Information Provided By Interim PET in Patients with Aggressive Lymphomas. <i>Blood</i> , 2015, 126, 3880-3880.	1.4	0
27	Interim PET-Based Outcome Prediction in Diffuse Large B-Cell Lymphoma Patients Participating in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL) Trial: Comparison of the Delta SUV Max Method and the Deauville 5-Point Scale. <i>Blood</i> , 2018, 132, 1696-1696.	1.4	0